Physician profile
Kyle Secoy
NPI 1730812363
$3,781.57
in general payments reported to CMS, 2019-2025
22 companies · $916 in 2025
The $916 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $126 · 2023: $1,509 · 2024: $1,230 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,099.19 | 2022-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $936.12 | 2022-2025 | Descovy, Yeztugo |
| Astrazeneca Pharmaceuticals LP | $255.57 | 2024-2025 | Airsupra, Farxiga |
| Hologic Sales and Service, LLC | $168.94 | 2023-2024 | Aptima, Affirm Prone Biopsy System |
| Abbvie INC. | $150.96 | 2024-2025 | |
| Axsome Therapeutics, INC. | $148.57 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $145.96 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $143.93 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $90.80 | 2024-2025 | |
| Exact Sciences Corporation | $88.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $79.38 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.70 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $63.02 | 2024-2025 | Spravato |
| Janssen Biotech, INC. | $61.55 | 2022-2023 | Symtuza |
| Amgen INC. | $61.11 | 2024-2025 | Repatha, Otezla, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $51.16 | 2023 | Serostim |
| Merck Sharp & Dohme LLC | $46.99 | 2025 | Gardasil 9, Capvaxive |
| Abbott Laboratories | $44.13 | 2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $23.96 | 2023 | Lyvispah |
| Esperion Therapeutics, INC. | $22.29 | 2025 | Nexletol |
| Astellas Pharma US INC | $21.98 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Secoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.